Department of Error (DOI:10.1016/S0140-6736(09)60403-7);Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

The Lancet

Volumn 373, Issue 9664, 2009, Pages 649-658

  Rosenson, Robert S ^a   Hislop, Colin ^c   McConnell, Daniel ^b   Elliott, Michael ^c   Stasiv, Yuri ^c   Wang, Nan ^d   Waters, David D ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Anthera Pharmaceuticals   (United States)

^d Pharm Olam International   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 002; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; SECRETORY PHOSPHOLIPASE A2; THIENOPYRIDINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VARESPLADIB; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HEADACHE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; UKRAINE; UNITED STATES;

EID: 60249101701     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60909-0     Document Type: Erratum

References (33)

1. 2 superfamily and its group numbering. Biochim Biophys Acta 1761 (2006) 1246-1259
2. Menschikowski M., Kasper M., Lattke P., et al. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 118 (1995) 173-181
3. Elinder L.S., Dumitrescu A., Larsson P., Hedin U., Frostegard J., and Claesson H.-E. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 17 (1997) 2257-2263
4. Hurt-Camejo E., Andersen S., Standal R., et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol 17 (1997) 300-309
5. Rosengren B., Peilot H., Umaerus M., et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet. Arterioscler Thromb Vasc Biol 26 (2006) 1579-1585
6. Bostrom M.A., Boyanovsky B.B., Jordan C.T., et al. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 27 (2007) 600-606
7. Hanasaki K., Yamada K., Yamamoto S., et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem 277 (2002) 29116-29124
8. Ivandic B., Castellani L.W., Wang X.P., et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 19 (1999) 1284-1290
9. Flood C., Gustafsson M., Pitas R.E., Arnaboldi L., Walzem R.L., and Boren J. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol 24 (2004) 564-570
10. Kleinman Y., Krul E.S., Burnes M., Aronson W., Pfleger B., and Schonfeld G. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J Lipid Res 29 (1988) 729-743
11. Sartipy P., Camejo G., Svensson L., and Hurt-Camejo E. Phospholipase A2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 274 (1999) 25913-25920
12. Hakala J.K., Oorni K., Pentikainen M.O., Hurt-Camejo E., and Kovanen P.T. Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 21 (2001) 1053-1058
13. Wooton-Kee C.R., Boyanovsky B.B., Nasser M.S., de Villiers W.S., and Webb N.R. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol 24 (2004) 762-767
14. Ghesquiere S.I., Gijbels M.J., Anthonsen M., et al. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J Lipid Res 46 (2005) 201-210
15. Jonsson-Rylander A.C., Lundin S., Rosengren B., Pettersson C., and Hurt-Camejo E. Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 10 (2008) 252-259
16. Kugiyama K., Ota Y., Takazoe K., et al. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation 100 (1999) 1280-1284
17. Liu P.Y., Li Y.H., Tsai W.C., et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 24 (2003) 1824-1832
18. Kugiyama K., Ota Y., Sugiyama S., et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 86 (2000) 718-722
19. Porela P., Pulkki K., Voipio-Pulkki L.M., Pettersson K., Leppänen V., and Nevalainen T.J. Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Res Cardiol 95 (2000) 413-417
20. Mallat Z., Benessiano J., Simon T., et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-NORFOLK Study. Arterioscler Thromb Vasc Biol 27 (2007) 1177-1183
21. Oslund R.C., Cermak N., and Gelb M.H. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J Med Chem 51 (2008) 4708-4714
22. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
23. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
24. Abraham E., Naum C., Bandi V., et al. Efficacy and safety of LY315920Na.S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 31 (2003) 718-728
25. Nyyssönen K.K., Kaikkonen J.J., and Salonen J.T. Characterization and determinants of an electronegatively charged low-density lipoprotein in human plasma. Scand J Clin Lab Invest 56 (1996) 681-689
26. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
27. Grundy S.M., Cleeman J.I., Merz C.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 44 (2004) 720-732
28. Beck S., Lambeau G., Scholz-Pedretti K., et al. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J Biol Chem 278 (2003) 29799-29812
29. Mohler E.R., Ballantyne C.M., Davidson M.H., et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51 (2008) 1632-1641
30. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 (2003) 152-160
31. Fraser H., Hislop C., Christie R.M., et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE -/- mice. J Cardiovasc Pharmacol 53 (2009) 60-65
32. Shaposhnik Z., Wang X., Trias J., et al. The synergistic inhibition of atherogenesis in ApoE -/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res (2008) 10.1194/jlr.m800361-JLR200 published Nov 21.
33. Masuda S., Murakami M., Ishikawa Y., Ishii T., and Kudo I. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim Biophys Acta 1736 (2005) 200-210